The restriction factors of human immunodeficiency virus

Journal of Biological Chemistry

Volumn 287, Issue 49, 2012, Pages 40875-40883

  Harris, Reuben S ^a   Hultquist, Judd F ^a   Evans, David T ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR PROTEINS; HUMAN IMMUNODEFICIENCY VIRUS; PREMATURE TERMINATION; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION; THERAPEUTIC INTERVENTION; VIRAL GENOME;

PROTEINS; VIRUSES;

DISEASES;

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CELL PROTEIN; COMPLEMENTARY DNA; MEMBRANE PROTEIN; RESTRICTION FACTOR; TETHERIN INTEGRAL MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN;

AMINO ACID SEQUENCE; DEAMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENVELOPE; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, CD; CYTOSINE DEAMINASE; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; GPI-LINKED PROTEINS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MACACA; MODELS, BIOLOGICAL; MONOMERIC GTP-BINDING PROTEINS; REVERSE TRANSCRIPTION; T-LYMPHOCYTES; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84870335313     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R112.416925     Document Type: Short Survey

References (100)

1. Rahm, N., and Telenti, A. (2012) The role of tripartite motif family members in mediating susceptibility to HIV-1 infection. Curr. Opin. HIVAIDS 7, 180-186
2. Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., and Martin, M. A. (1987) The HIV A (sor) gene product is essential for virus infectivity. Nature 328, 728-730 (Pubitemid 17125778)
3. + T lymphocytes. J. Virol. 66, 6489-6495
4. Simon, J. H., Gaddis, N. C., Fouchier, R. A., and Malim, M. H. (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4, 1397-1400 (Pubitemid 28553462)
5. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650
6. Harris, R. S., Petersen-Mahrt, S. K., and Neuberger, M. S. (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247-1253 (Pubitemid 35453840)
7. Vartanian, J. P., Meyerhans, A., Asjö, B., and Wain-Hobson, S. (1991) Selection, recombination, andG3Ahypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65, 1779-1788
8. + T cells. J. Virol. 75, 7973-7986
9. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809 (Pubitemid 36724943)
10. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (Pubitemid 36834849)
11. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98 (Pubitemid 36834848)
12. Miyagi, E., Opi, S., Takeuchi, H., Khan, M., Goila-Gaur, R., Kao, S., and Strebel, K. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81, 13346-13353 (Pubitemid 350247831)
13. Schumacher, A. J., Haché, G., MacDuff, D. A., Brown, W. L., and Harris, R. S. (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82, 2652-2660 (Pubitemid 351329156)
14. Browne, E. P., Allers, C., and Landau, N. R. (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387, 313-321
15. Yu, Q., König, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J. M., and Landau, N. R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442 (Pubitemid 38568947)
16. Chelico, L., Pham, P., Calabrese, P., and Goodman, M. F. (2006) APOBEC3G DNA deaminase acts processively 3′ → 5′ on singlestranded DNA. Nat. Struct. Mol. Biol. 13, 392-399 (Pubitemid 43881578)
17. Malim, M. H., and Emerman, M. (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3, 388-398 (Pubitemid 351784365)
18. Albin, J. S., and Harris, R. S. (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12, e4
19. Hultquist, J. F., Lengyel, J. A., Refsland, E. W., LaRue, R. S., Lackey, L., Brown, W. L., and Harris, R. S. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220-11234
20. Refsland, E. W., Hultquist, J. F., and Harris, R. S. (2012) Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8, e1002800
21. OhAinle, M., Kerns, J. A., Li, M. M., Malik, H. S., and Emerman, M. (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4, 249-259
22. Wang, X., Abudu, A., Son, S., Dang, Y., Venta, P. J., and Zheng, Y. H. (2011) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85, 3142-3152
23. LaRue, R. S., Lengyel, J., Jónsson, S. R., Andrésdó ttir, V., and Harris, R. S. (2010) Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J. Virol. 84, 8193-8201
24. Compton, A. A., Hirsch, V. M., and Emerman, M. (2012) The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe 11, 91-98
25. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060 (Pubitemid 37386201)
26. Mehle, A., Goncalves, J., Santa-Marta, M., McPike, M., and Gabuzda, D. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866 (Pubitemid 39602304)
27. Jäger, S., Kim, D. Y., Hultquist, J. F., Shindo, K., LaRue, R. S., Kwon, E., Li, M., Anderson, B. D., Yen, L., Stanley, D., Mahon, C., Kane, J., Franks-Skiba, K., Cimermancic, P., Burlingame, A., Sali, A., Craik, C. S., Harris, R. S., Gross, J. D., and Krogan, N. J. (2012) Vif hijacks CBFβ to degrade APOBEC3G and promote HIV-1 infection. Nature 481, 371-375
28. Zhang, W., Du, J., Evans, S. L., Yu, Y., and Yu, X. F. (2012) T-cell differentiation factor CBFβ regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376-379
29. Harris, R. S. (2008) Enhancing immunity to HIV through APOBEC. Nat. Biotechnol. 26, 1089-1090
30. Pillai, S. K., Wong, J. K., and Barbour, J. D. (2008) Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5, 26
31. Van Damme, N., Goff, D., Katsura, C., Jorgenson, R. L., Mitchell, R., Johnson, M. C., Stephens, E. B., and Guatelli, J. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-252 (Pubitemid 351494713)
32. Neil, S. J., Zang, T., and Bieniasz, P. D. (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425-430 (Pubitemid 351158893)
33. Strebel, K., Klimkait, T., and Martin, M. A. (1988) A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241, 1221-1223
34. Geraghty, R. J., Talbot, K. J., Callahan, M., Harper, W., and Panganiban, A. T. (1994) Cell type dependence for Vpu function. J. Med. Primatol. 23, 146-150
35. Varthakavi, V., Smith, R. M., Bour, S. P., Strebel, K., and Spearman, P. (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. U.S.A. 100, 15154-15159 (Pubitemid 37518032)
36. Neil, S. J., Eastman, S. W., Jouvenet, N., and Bieniasz, P. D. (2006) HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2, e39
37. Neil, S. J., Sandrin, V., Sundquist, W. I., and Bieniasz, P. D. (2007) An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2, 193-203 (Pubitemid 47355204)
38. Kupzig, S., Korolchuk, V., Rollason, R., Sugden, A., Wilde, A., and Banting, G. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4, 694-709 (Pubitemid 37168591)
39. Perez-Caballero, D., Zang, T., Ebrahimi, A., McNatt, M. W., Gregory, D. A., Johnson, M. C., and Bieniasz, P. D. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139, 499-511
40. Hammonds, J., Wang, J.-J., Yi, H., and Spearman, P. (2010) Immunoelectron microscopic evidence for tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 6, e1000749
41. Fitzpatrick, K., Skasko, M., Deerinck, T. J., Crum, J., Ellisman, M. H., and Guatelli, J. (2010) Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog. 6, e1000701
42. Miyakawa, K., Ryo, A., Murakami, T., Ohba, K., Yamaoka, S., Fukuda, M., Guatelli, J., and Yamamoto, N. (2009) BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog. 5, e1000700
43. Kobayashi, T., Ode, H., Yoshida, T., Sato, K., Gee, P., Yamamoto, S. P., Ebina, H., Strebel, K., Sato, H., and Koyanagi, Y. (2011) Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J. Virol. 85, 932-945
44. Iwabu, Y., Fujita, H., Kinomoto, M., Kaneko, K., Ishizaka, Y., Tanaka, Y., Sata, T., and Tokunaga, K. (2009) HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 284, 35060-35072
45. Rong, L., Zhang, J., Lu, J., Pan, Q., Lorgeoux, R.-P., Aloysius, C., Guo, F., Liu, S.-L., Wainberg, M. A., and Liang, C. (2009) The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 83, 7536-7546
46. Douglas, J. L., Viswanathan, K., McCarroll, M. N., Gustin, J. K., Früh, K., and Moses, A. V. (2009) Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/tetherin via a βTrCP-dependent mechanism. J. Virol. 83, 7931-7947
47. Mangeat, B., Gers-Huber, G., Lehmann, M., Zufferey, M., Luban, J., and Piguet, V. (2009) HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its β-TrCP2-dependent degradation. PLoS Pathog. 5, e1000574
48. Mitchell, R. S., Katsura, C., Skasko, M. A., Fitzpatrick, K., Lau, D., Ruiz, A., Stephens, E. B., Margottin-Goguet, F., Benarous, R., and Guatelli, J. C. (2009) Vpu antagonizes BST-2-mediated restriction of HIV-1 release via β-TrCP and endo-lysosomal trafficking. PLoS Pathog 5, e1000450
49. Gustin, J. K., Douglas, J. L., Bai, Y., and Moses, A. V. (2012) Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain. J. Biol. Chem. 287, 14837-14850
50. Tokarev, A. A., Munguia, J., and Guatelli, J. C. (2011) Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J. Virol. 85, 51-63
51. Janvier, K., Pelchen-Matthews, A., Renaud, J.-B., Caillet, M., Marsh, M., and Berlioz-Torrent, C. (2011) The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog. 7, e1001265
52. Caillet, M., Janvier, K., Pelchen-Matthews, A., Delcroix-Genête, D., Camus, G., Marsh, M., and Berlioz-Torrent, C. (2011) Rab7A is required for efficient production of infectious HIV-1. PLoS Pathog. 7, e1002347
53. Tervo, H.-M., Homann, S., Ambiel, I., Fritz, J. V., Fackler, O. T., and Keppler, O. T. (2011) β-TrCP is dispensable for Vpu's ability to overcome the CD317/tetherin-imposed restriction to HIV-1 release. Retrovirology 8, 9
54. Dubé, M., Roy, B. B., Guiot-Guillain, P., Binette, J., Mercier, J., Chiasson, A., and Cohen, E. A. (2010) Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6, e1000856
55. Schmidt, S., Fritz, J. V., Bitzegeio, J., Fackler, O. T., and Keppler, O. T. (2011) HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2, e00036-00011
56. Dubé, M., Paquay, C., Roy, B. B., Bego, M. G., Mercier, J., and Cohen, E. A. (2011) HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 12, 1714-1729
57. Lau, D., Kwan, W., and Guatelli, J. (2011) Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J. Virol. 85, 9834-9846
58. Serra-Moreno, R., Jia, B., Breed, M., Alvarez, X., and Evans, D. T. (2011) Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic Nef-deleted SIV. Cell Host Microbe 9, 46-57
59. Gupta, R. K., Mlcochova, P., Pelchen-Matthews, A., Petit, S. J., Mattiuzzo, G., Pillay, D., Takeuchi, Y., Marsh, M., and Towers, G. (2009) Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U. S. A. 106, 20889-20894
60. Le Tortorec, A., and Neil, S. J. (2009) Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83, 11966-11978
61. Jia, B., Serra-Moreno, R., Neidermyer, W., Rahmberg, A., Mackey, J., Fofana, I. B., Johnson, W. E., Westmoreland, S., and Evans, D. T. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5, e1000429
62. Bour, S., Schubert, U., Peden, K., and Strebel, K. (1996) The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J. Virol. 70, 820-829 (Pubitemid 26028997)
63. Hauser, H., Lopez, L. A., Yang, S. J., Oldenburg, J. E., Exline, C. M., Guatelli, J. C., and Cannon, P. M. (2010) HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7, 51
64. Lopez, L. A., Yang, S. J., Hauser, H., Exline, C. M., Haworth, K. G., Oldenburg, J., and Cannon, P. M. (2010) Ebola virus glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84, 7243-7255
65. Gupta, R. K., Hué, S., Schaller, T., Verschoor, E., Pillay, D., and Towers, G. J. (2009) Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5, e1000443
66. Bour, S., Akari, H., Miyagi, E., and Strebel, K. (2003) Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309, 85-98 (Pubitemid 36506592)
67. Sauter, D., Schindler, M., Specht, A., Landford, W. N., Münch, J., Kim, K.-A., Votteler, J., Schubert, U., Bibollet-Ruche, F., Keele, B. F., Takehisa, J., Ogando, Y., Ochsenbauer, C., Kappes, J. C., Ayouba, A., Peeters, M., Learn, G. H., Shaw, G., Sharp, P. M., Bieniasz, P., Hahn, B. H., Hatziioannou, T., and Kirchhoff, F. (2009) Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6, 409-421
68. Zhang, F., Wilson, S. J., Landford, W. C., Virgen, B., Gregory, D., Johnson, M. C., Munch, J., Kirchhoff, F., Bieniasz, P. D., and Hatziioannou, T. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6, 54-67
69. Zhang, F., Landford, W. N., Ng, M., McNatt, M. W., Bieniasz, P. D., and Hatziioannou, T. (2011) SIV Nef proteins recruit the AP-2 complex to antagonize tetherin and facilitate virion release. PLoS Pathog. 7, e1002039
70. Zhou, J., Zhang, Z., Mi, Z., Wang, X., Zhang, Q., Li, X., Liang, C., and Cen, S. (2012) Characterization of the interface of the bone marrow stromal cell antigen 2-Vpu protein complex via computational chemistry. Biochemistry 51, 1288-1296
71. Skasko, M., Wang, Y., Tian, Y., Tokarev, A., Munguia, J., Ruiz, A., Stephens, E. B., Opella, S. J., and Guatelli, J. (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helixhelix interactions. J. Biol. Chem. 287, 58-67
72. Guyader, M., Emerman, M., Montagnier, L., and Peden, K. (1989) VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J. 8, 1169-1175 (Pubitemid 19273285)
73. Kappes, J. C., Conway, J. A., Lee, S. W., Shaw, G. M., and Hahn, B. H. (1991) Human immunodeficiency virus type 2 Vpx protein augments viral infectivity. Virology 184, 197-209
74. Yu, X. F., Yu, Q. C., Essex, M., and Lee, T. H. (1991) The vpx gene of simian immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and macrophage. J. Virol. 65, 5088-5091
75. Nègre, D., Mangeot, P. E., Duisit, G., Blanchard, S., Vidalain, P. O., Leissner, P., Winter, A. J., Rabourdin-Combe, C., Mehtali, M., Moullier, P., Darlix, J. L., and Cosset, F. L. (2000) Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 7, 1613-1623
76. Goujon, C., Arfi, V., Pertel, T., Luban, J., Lienard, J., Rigal, D., Darlix, J. L., and Cimarelli, A. (2008) Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J. Virol. 82, 12335-12345
77. Goujon, C., Rivière, L., Jarrosson-Wuilleme, L., Bernaud, J., Rigal, D., Darlix, J. L., and Cimarelli, A. (2007) SIVSM/HIV-2 Vpx proteins pro- mote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 4, 2
78. Kaushik, R., Zhu, X., Stranska, R., Wu, Y., and Stevenson, M. (2009) A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe 6, 68-80
79. Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Ségéral, E., Yatim, A., Emiliani, S., Schwartz, O., and Benkirane, M. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654-657
80. Hrecka, K., Hao, C., Gierszewska, M., Swanson, S. K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M. P., and Skowronski, J. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658-661
81. Vorontsov, I. I., Minasov, G., Kiryukhina, O., Brunzelle, J. S., Shuvalova, L., and Anderson, W. F. (2011) Characterization of the deoxynucleotide triphosphate triphosphohydrolase (dNTPase) activity of the EF1143 protein from Enterococcus faecalis and crystal structure of the activatorsubstrate complex. J. Biol. Chem. 286, 33158-33166
82. Powell, R. D., Holland, P. J., Hollis, T., and Perrino, F. W. (2011) The Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 286, 43596-43600
83. Goldstone, D. C., Ennis-Adeniran, V., Hedden, J. J., Groom, H. C., Rice, G. I., Christodoulou, E., Walker, P. A., Kelly, G., Haire, L. F., Yap, M. W., de Carvalho, L. P., Stoye, J. P., Crow, Y. J., Taylor, I. A., and Webb, M. (2011) HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379-382
84. Kim, B., Nguyen, L. A., Daddacha, W., and Hollenbaugh, J. A. (2012) Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocytederived macrophages. J. Biol. Chem. 287, 21570-21574
85. Lahouassa, H., Daddacha, W., Hofmann, H., Ayinde, D., Logue, E. C., Dragin, L., Bloch, N., Maudet, C., Bertrand, M., Gramberg, T., Pancino, G., Priet, S., Canard, B., Laguette, N., Benkirane, M., Transy, C., Landau, N. R., Kim, B., and Margottin-Goguet, F. (2012) SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13, 223-228
86. Ahn, J., Hao, C., Yan, J., DeLucia, M., Mehrens, J., Wang, C., Gronenborn, A. M., and Skowronski, J. (2012) HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J. Biol. Chem. 287, 12550-12558
87. Wei, W., Guo, H., Han, X., Liu, X., Zhou, X., Zhang, W., and Yu, X. F. (2012) A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest. Cell Microbiol. 14, 1745-1756
88. Laguette, N., Rahm, N., Sobhian, B., Chable-Bessia, C., Münch, J., Snoeck, J., Sauter, D., Switzer, W. M., Heneine, W., Kirchhoff, F., Delsuc, F., Telenti, A., and Benkirane, M. (2012) Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe 11, 205-217
89. Lim, E. S., Fregoso, O. I., McCoy, C. O., Matsen, F. A., Malik, H. S., and Emerman, M. (2012) The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 11, 194-204
90. Zhang, C., de Silva, S., Wang, J. H., and Wu, L. (2012) Co-evolution of primate SAMHD1 and lentivirus Vpx leads to the loss of the vpx gene in HIV-1 ancestor. PloS ONE 7, e37477
91. Manel, N., and Littman, D. R. (2011) Hiding in plain sight: how HIV evades innate immune responses. Cell 147, 271-274
92. Kestler, H. W., 3rd, Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., and Desrosiers, R. C. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662
93. Miller, M. D., Warmerdam, M. T., Gaston, I., Greene, W. C., and Feinberg, M. B. (1994) The human immunodeficiency virus 1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J. Exp. Med. 179, 101-113 (Pubitemid 24012975)
94. Aiken, C., and Trono, D. (1995) Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 69, 5048-5056
95. Casey, L., Wen, X., and de Noronha, C. M. (2010) The functions of the HIV-1 protein Vpr and its action through the DCAF1·DDB1·Cullin4 ubiquitin ligase. Cytokine 51, 1-9
96. Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissier, P., and Sodroski, J. (2004) The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (Pubitemid 38297747)
97. Yap, M. W., Nisole, S., and Stoye, J. P. (2005) A single amino acid change in the SPRY domain of human TRIM5α leads to HIV-1 restriction. Curr. Biol. 15, 73-78 (Pubitemid 40084706)
98. Li, Y., Li, X., Stremlau, M., Lee, M., and Sodroski, J. (2006) Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 80, 6738-6744 (Pubitemid 44025173)
99. Albin, J. S., Haché, G., Hultquist, J. F., Brown, W. L., and Harris, R. S. (2010) Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 84, 10209-10219
100. Haché, G., Abbink, T. E., Berkhout, B., and Harris, R. S. (2009) Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol. 83, 5956-5960